Pfizer to Discontinue P-III (REALM-DCM) Trial of PF-07265803 for the Treatment of LMNA-Related Dilated Cardiomyopathy

Published: Aug 5, 2022 | Tags: Pfizer, PF-07265803, LMNA-Related Dilated Cardiomyopathy, Clinical Trial, P-III, REALM-DCM Trial

AstraZeneca Entered into a Two-Year Collaboration with Thorne HealthTech for Disease Discovery System to Advance Novel Product Development

Published: Aug 5, 2022 | Tags: AstraZeneca, Thorne HealthTech, Disease Discovery System, Pharma, multi-omic platform, AI model

Innovent Entered into a Collaboration and License Agreement with Sanofi to Advance Development of Therapies for Cancer in China

Published: Aug 5, 2022 | Tags: Innovent Sanofi, Cancer, SAR408701, SAR444245, Pharma, China

Scynexis Presents P-III (CANDLE) Study Results of Ibrexafungerp for the Prevention of Recurrent Vaginal Yeast Infections at IDSOG 2022

Published: Aug 5, 2022 | Tags: Scynexis, Ibrexafungerp, Recurrent Vaginal Yeast Infections, Clinical Trial, P-III (CANDLE) Study, IDSOG, 2022

Grünenthal Entered into a License Agreement with Shionogi for Resiniferatoxin (RTX) to Treat Pain Associated with Knee Osteoarthritis

Published: Aug 5, 2022 | Tags: Grünenthal, Shionogi, Resiniferatoxin, RTX, Knee Osteoarthritis, Pharma

Amgen to Acquire Chemocentryx for ~$4B

Published: Aug 5, 2022 | Tags: Amgen, Chemocentryx, Tavneos, Otezla, Enbrel, Tezspire, Amgevita, Riabni & Avsola Autoimmune Diseases, Inflammatory Disorders, Cancer, Acquire, ~$4B

Alnylam Reports P-III (APOLLO-B) Trial Results of Patisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Published: Aug 4, 2022 | Tags: Alnylam, Patisiran, ATTR Amyloidosis, Cardiomyopathy, Clinical Trial, P-III APOLLO-B Trial

AstraZeneca and MSD’s Lynparza (olaparib) Receive EC’s Approval as Adjuvant Treatment for Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

Published: Aug 4, 2022 | Tags: AstraZeneca, MSD, Lynparza, Olaparib, Germline BRCA-Mutated, Breast Cancer, Regulatory, EC, Approval

Radiopharm Entered into an Agreement with Lantheus for the Development of NM-01

Published: Aug 4, 2022 | Tags: Radiopharm, Lantheus, NanoMab, NM-01, Non-Small Cell Lung Cancer, Pharma

Sumitomo Pharma Oncology’s DSP-5336 Receives the US FDA’s Orphan Drug Designation for the Treatment of Acute Myeloid Leukemia

Published: Aug 4, 2022 | Tags: Sumitomo Pharma Oncology, DSP-5336, Acute Myeloid Leukemia, Regulatory, US, FDA, Orphan Drug Designation

Poseida Entered into a Collaboration and License Agreement with Roche for Allogeneic CAR-T Cell Therapies to Treat Hematologic Malignancies

Published: Aug 4, 2022 | Tags: Poseida, Roche, Allogeneic CAR-T Cell Therapies, BCMA-ALLO1, P-CD19CD20-ALLO1, P-BCMACD19-ALLO1, P-CD70-ALLO1, Hematologic Malignancies, Biotech

Kiniksa Entered into a Global License Agreement with Genentech to Develop and Commercialize Vixarelimab for Fibrosis

Published: Aug 4, 2022 | Tags: Kiniksa, Genentech, Vixarelimab, Fibrosis, Prurigo Nodularis, Pharma

AbCellera Collaborated with Atlas Venture to Discover Therapeutic Antibodies Against Three Drug Targets

Published: Aug 3, 2022 | Tags: AbCellera, Atlas Venture, Therapeutic Antibodies, Biotech

Merck and Eisai Provide P-III (LEAP-002) Trial Update of Keytruda (pembrolizumab) + Lenvima (lenvatinib) for Unresectable Hepatocellular Carcinoma

Published: Aug 3, 2022 | Tags: Merck, Eisai, Keytruda, pembrolizumab, Lenvima, Lenvatinib, Hepatocellular Carcinoma, Clinical Trial, P-III LEAP-002 Trial

Context and Menarini Entered into a Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR + Elacestrant for Metastatic Breast Cancer

Published: Aug 3, 2022 | Tags: Context, Menarini, ONA-XR, Elacestrant, Metastatic Breast Cancer, Pharma

TransCode Collaborated with MD Anderson to Advance RNA Therapies for the Treatment of Cancer

Published: Aug 3, 2022 | Tags: TransCode, MD Anderson, RNA Therapies, Oncology, Biotech

Coherus’ Cimerli (biosimilar, ranibizumab) Receives the US FDA’s Approval as a First Interchangeable Biosimilar for the Treatment of Retinal Disease

Published: Aug 3, 2022 | Tags: Coherus, Cimerli, biosimilar, ranibizumab, Retinal Disease, Regulatory, Interchangeable Biosimilar, US, FDA, Approval

Rigel Entered into an Exclusive WW License Agreement with Forma to Develop and Commercialize Olutasidenib for Acute Myeloid Leukemia

Published: Aug 2, 2022 | Tags: Rigel, Forma, Olutasidenib, Acute Myeloid Leukemia, Pharma

Caris Life Sciences Entered into a Multi-Year Strategic Option and License Agreement with Xencor for Novel XmAb Bispecific Antibodies to Treat Cancer

Published: Aug 2, 2022 | Tags: Caris Life Sciences, Xencor, Novel XmAb Bispecific Antibodies, Cancer, Biotech, XmAb Engineering Platform

Roche Reports P-III (IMscin001) Study Results of Subcutaneous Formulation of Tecentriq for the Treatment of Non-Small Cell Lung Cancer

Published: Aug 2, 2022 | Tags: Roche, Tecentriq, Non-Small Cell Lung Cancer, Clinical Trial, P-III IMscin001 Study

Nyxoah Entered into a Distribution Agreement with Acurable for AcuPebble SA100 Home Sleep Test to Treat Obstructive Sleep Apnea in Germany

Published: Aug 2, 2022 | Tags: Nyxoah, Acurable, AcuPebble SA100 Home Sleep Test, Obstructive Sleep Apnea, Medtech, Germany

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patients

Published: Aug 2, 2022 | Tags: Janssen, Stelara, ustekinumab, Active Psoriatic Arthritis, Regulatory, US, FDA, Approval, STELARA withMe Support Program

Avalo Entered into an Exclusive WW License Agreement with Apollo to Develop and Commercialize AVTX-007 (camoteskimab) for Non-Eosinophilic Asthma

Published: Aug 2, 2022 | Tags: Avalo, Apollo, AVTX-007, camoteskimab, Non-Eosinophilic Asthma, Pharma, P-II (PEAK) Trial

Sosei Heptares Entered into a Research Collaboration and Option to License Agreement with AbbVie for Novel Therapies to Treat Neurological Diseases

Published: Aug 1, 2022 | Tags: Sosei Heptares, AbbVie, Novel Therapies, Neurological Diseases, Pharma, Heptares’ StaR Technology, SBDD Platform, GPCR Targets

Arecor to Acquire Tetris Pharma for Ogluo

Published: Aug 1, 2022 | Tags: Arecor, Tetris Pharma, Ogluo, Gvoke PFS, Gvoke HypoPen, Hypoglycaemia, Diabetes, M&A, Acquire

HUTCHMED Reports the Initiation of Tazemetostat in Bridging Study for the Treatment of Follicular Lymphoma in China

Published: Aug 1, 2022 | Tags: HUTCHMED, Tazemetostat, Follicular Lymphoma, Clinical Trial, Bridging Study, China

Arcutis’ Zoryve (roflumilast) Receives the US FDA's NDA Approval for Plaque Psoriasis in Individuals Aged ≥12 Years

Published: Aug 1, 2022 | Tags: Arcutis, Zoryve, roflumilast, Plaque Psoriasis, Regulatory, US, FDA, NDA, Approval

Novo Nordisk Reports P-IIIa (ONWARDS 3 & 4) Trials Results of Insulin Icodec for the Treatment of Type 2 Diabetes

Published: Aug 1, 2022 | Tags: Novo Nordisk, Insulin Icodec, Type 2 Diabetes, P-IIIa, ONWARDS 3 & 4 Trials, Clinical Trial, Type 2 Diabetes

ViiV Healthcare Presents Five-Year P-III (BRIGHTE) Study Results of Fostemsavir for Multidrug-Resistant HIV-1 Infection at AIDS 2022

Published: Aug 1, 2022 | Tags: ViiV Healthcare, Fostemsavir, Multidrug-Resistant, HIV-1 Infection, Clinical Trial, P-III BRIGHTE Study, AIDS 2022

Ipsen Collaborated with Marengo Therapeutics to Advance Two Precision Immuno-Oncology Therapies Using STAR Platform

Published: Aug 1, 2022 | Tags:  Ipsen, Marengo Therapeutics, Precision Immuno-Oncology Therapies, STAR Platform, Cancer, Pharma, TCR Vβ-Targeted Precision T Cell

Related Post: PharmaShots Weekly Snapshots (July 25 – 29, 2022)